SCHEMBL3181237

SCHEMBL3181237

CCOC(=O)C1(F)CCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 3/20 0.39
TRPA1 O75762 1/20 0.38
POLB P06746 1/20 0.38
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
OPRM1 P35372 7/20 0.37
ATM Q13315 1/20 0.36
OPRD1 P41143 3/20 0.36
OPRK1 P41145 3/20 0.36
ALOX15 P16050 2/20 0.36
SLC22A1 O15245 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADRA1A P35348 1/20 0.36
KCNH2 Q12809 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10477634 0.96 SMN1; SMN2 (0.40) SMN1; SMN2MEN1KMT2AALDH1A1TRPA1
SCHEMBL10477609 0.94 SMN1; SMN2 (0.39) SMN1; SMN2MEN1KMT2AALDH1A1TRPA1
SCHEMBL16058884 0.85 SMN1; SMN2 (0.39) SMN1; SMN2MEN1KMT2AALDH1A1TRPA1
SCHEMBL31277004 0.85 ALDH1A1 (0.37) SMN1; SMN2MEN1KMT2AALDH1A1TRPA1
SCHEMBL23883448 0.82 POLB (0.35) SMN1; SMN2MEN1KMT2AALDH1A1TRPA1
SCHEMBL407780 0.82 OPRM1 (0.51) SMN1; SMN2MEN1KMT2AALDH1A1TRPA1
Hydrochloric Acid SCHEMBL440141 0.80 OPRM1 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1TRPA1
SCHEMBL12049755 0.80 OPRM1 (0.53) OPRM1OPRD1OPRK1SLC22A1SLC6A4
SCHEMBL23411132 0.80 OPRM1 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1TRPA1
SCHEMBL16549502 0.80 OPRM1 (0.53) OPRM1OPRD1OPRK1SLC22A1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294500-A1 ISOINDOLINONE COMPOUNDS, AND USES THEREOF HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD. (CN) 2024-09-05 US disclosed
EP-4352046-A1 ISOINDOLINONE COMPOUNDS, AND USES THEREOF Hangzhou Glubio Pharmaceutical Co., Ltd. (CN) 2024-04-17 EP disclosed
CN-117561244-A Isoindolinone compounds and uses thereof 杭州格博生物医药有限公司 2024-02-13 CN disclosed
WO-2022257897-A1 ISOINDOLINONE COMPOUNDS, AND USES THEREOF HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD. (CN) 2022-12-15 WO disclosed
WO-2022257897-A1 ISOINDOLINONE COMPOUNDS, AND USES THEREOF HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD. (CN) 2022-12-15 WO disclosed
US-11261164-B2 Small molecule agonists of neurotensin receptor 1 Sanford Burnham Prebys Medical Discovery Institute (US) 2022-03-01 US disclosed
US-20200354324-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2020-11-12 US disclosed
US-20200354324-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2020-11-12 US disclosed
US-10584103-B2 Small molecule agonists of neurotensin receptor 1 Sanford Burnham Prebys Medical Discovery Institute (US) 2020-03-10 US disclosed
US-20190023665-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 Sanford Burnham Prebys Medical Discovery Institute 2019-01-24 US disclosed
EP-1943243-B1 KINASE INHIBITORS LILLY CO ELI (US) 2010-12-29 EP disclosed
US-7652015-B2 Suppression cytokines , tumor necrosis factor ELI LILLY AND COMPANY (US) 2010-01-26 US disclosed
US-7582638-B2 Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors ELI LILLY AND COMPANY (US) 2009-09-01 US disclosed
US-20080275056-A1 With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis ELI LILLY AND COMPANY 2008-11-06 US disclosed
US-20080269244-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-10-30 US disclosed
CN-101296924-A Pyrazole-isoquinoline urea derivatives as P38 kinase inhibitors LILLY CO ELI (US) 2008-10-29 CN disclosed
EP-1943244-A1 PYRAZOLE-ISOQUINOLINE UREA DERIVATIVES AS P38 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2008-07-16 EP disclosed
EP-1943243-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2008-07-16 EP disclosed
WO-2007053346-A1 PYRAZOLE-ISOQUINOLINE UREA DERIVATIVES AS P38 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-05-10 WO disclosed
WO-2007053394-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10584103-B2 Small molecule agonists of neurotensin receptor 1 NTSR1, NTSR2, VIPR1 SMN1; SMN2 939/4885MEN1 921/4885KMT2A 4362/4885
US-20240294500-A1 ISOINDOLINONE COMPOUNDS, AND USES THEREOF PKD1, SLC10A1, TP53 SMN1; SMN2 2168/4885MEN1 980/4885KMT2A 3381/4885
US-11261164-B2 Small molecule agonists of neurotensin receptor 1 NTSR1, NTSR2, VIPR1 SMN1; SMN2 939/4885MEN1 921/4885KMT2A 4362/4885
US-20080275056-A1 With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis CNKSR1, CHUK, SLC14A1 SMN1; SMN2 4317/4885MEN1 2250/4885KMT2A 1690/4885
US-20200354324-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 NTSR1, NTSR2, VIPR1 SMN1; SMN2 939/4885MEN1 921/4885KMT2A 4362/4885
US-20080269244-A1 Kinase Inhibitors MAP3K1, MAP3K20, MAP3K19 SMN1; SMN2 3849/4885MEN1 1164/4885KMT2A 697/4885
US-20190023665-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 NTSR1, NTSR2, VIPR1 SMN1; SMN2 939/4885MEN1 921/4885KMT2A 4362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.